Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Sangamo Therapeutics Logo
Sangamo Therapeutics Growth Score
81
CB Rank
37608
Heat Score
56
Sangamo researches, develops and commercializes engineered DNA-binding proteins for the development of novel therapeutic strategies.
Founded
obfuscation
PublicPost-IPO Equity Richmond, California, United States251-500 www.sangamo.com
Biotechnology
Genetics
Health Care
Pharmaceutical
Therapeutics
Overview

Sangamo Therapeutics
Total Funding
obfuscation
Growth Score
81
Heat Score
56

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score81
-8 pts
in past quarter
Heat Score 56
-5 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Sangamo Therapeutics

CB Rank
37608
Sangamo researches, develops and commercializes engineered DNA-binding proteins for the development of novel therapeutic strategies.
Founded
obfuscation
PublicPost-IPO Equity Richmond, California, United States251-500 www.sangamo.com
Biotechnology
Genetics
Health Care
Pharmaceutical
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Sangamo Therapeutics, Inc.
Operating Status Active
Stock Symbol  NASDAQ:SGMO
Company Type For Profit
Founders  Edward Lanphier
About the Company

Sangamo Therapeutics is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal

Storage Disorders, and Hemoglobinopathies.

Phone Number 5102368951
Contact Email info@sangamo.com
Predictions & Insights

Growth Insight

See this Growth Insight
Sangamo Therapeutics is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Zinc Finger Platform
A technology platform that engineers zinc finger proteins to target specific DNA sequences for therapeutic genome editing.
Delivery Platform
A system designed to deliver engineered DNA-binding proteins and gene editing tools into target cells for therapeutic purposes.

Research & Development

Sangamo Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 9
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Sangamo Therapeutics Logo
Post-IPO Equity - Sangamo Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Sangamo Therapeutics Logo
Post-IPO Equity - Sangamo Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Sangamo Therapeutics Logo
Post-IPO Equity - Sangamo Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Sangamo Therapeutics Logo
Post-IPO Equity - Sangamo Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Sangamo Therapeutics Logo
Post-IPO Equity - Sangamo Therapeutics
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 9
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Sangamo Therapeutics Logo
Post-IPO Equity - Sangamo Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Sangamo Therapeutics Logo
Post-IPO Equity - Sangamo Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Sangamo Therapeutics Logo
Post-IPO Equity - Sangamo Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Sangamo Therapeutics Logo
Post-IPO Equity - Sangamo Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Sangamo Therapeutics Logo
Post-IPO Equity - Sangamo Therapeutics
—
obfuscation
— Post-IPO Equity

Investors

Investments

Number of Acquisitions 2

Investment Breakdown

Number of Acquisitions 2
Market Intelligence
People
View Profiles & Contacts
Headcount 251-500 Employee Profiles 9 Board Members and Advisors 5 Contacts 360

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 9, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 8, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 22, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 4, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

7,487
-43.32%
 in past month

IT Spend

$1.8MThis year, Sangamo Therapeutics is projected to spend $1.8M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Mailing List Logo
Mailing List
100
Databricks Unity Catalog Logo
Databricks Unity Catalog
100
Failure Analysis Logo
Failure Analysis
100

Actively Used Products

28Sangamo Therapeutics uses 28 technology products and services including HTML5, GreenSock Animation Platform, and  Bootstrap, according to G2 Stack.

Active Website Tech Count

14Sangamo Therapeutics is actively using 14 technologies for its website, according to BuiltWith. These include IPv6, Pound Sterling, and  Japanese Yen.

Total IP

301The intellectual property of Sangamo Therapeutics includes 291 registered patents primarily in the 'Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation Or Genetic Engineering' category, according to IPqwery. Additionally, Sangamo Therapeutics has registered 10 trademarks with the most popular class being 'Chemical substances', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Sangamo Therapeutics's headquarters? Sangamo Therapeutics is located in Richmond, California, United States.Who invested in Sangamo Therapeutics? Sangamo Therapeutics has 2 investors including California Institute for Regenerative Medicine and  National Institutes of Health.When was the last funding round for Sangamo Therapeutics? Sangamo Therapeutics closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Sangamo Therapeutics's competitors? Alternatives and possible competitors to Sangamo Therapeutics may include Alnylam Pharmaceuticals, Hatteras Venture Partners, and  Strand Therapeutics.How much funding has Sangamo Therapeutics raised to date? Sangamo Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(53d292a 1)
|